Following initiation of elexacaftor/tezacaftor/ivacaftor, Lung Clearance Index decreases in children with cystic fibrosis, ...

Please provide your email address to receive an email when new articles are posted on . Three measures of lung function improved between baseline and 12 months. Observed improvements were not as large ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, ...

Peak nasal inspiratory flow (PNIF) measurement was a feasible, noninvasive method for assessing nasal airflow obstruction in children with cystic fibrosis and correlated significantly with nasal ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life, presumably even in ...

BUFFALO, N.Y. — A University at Buffalo psychiatrist who has played a critical role in getting mental health screening and treatment integrated into routine care for adults and adolescents with cystic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Neuropsychological side effects included insomnia, ...

Protein clustering mechanism on the cell membrane presents a new therapeutic target for cystic fibrosis. A new study from The Hospital for Sick Children (SickKids) reveals the process underlying ...